Effect of intracoronary injection of autologous stemm cells on left ventricular ejection fraction and volumes one year after an acute myocardial infarction. Efecto de la inyección intracoronaria de células madre obtenidas de sangre periférica sobre la fracción de eyección y los volúmenes del ventrículo izquierdo al año de haber padecido un infarto agudo de miocardio.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001772-20-ES

Enrollment

Registered

2006-06-30

Start date

2007-03-15

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The trial evaluates the effect on left ventricular function recovery of the intracoronary injection of mononuclear white cells obtained from peripheral blood in the week after an acute myocardial infaction.

Interventions

Product Name: stemm cells Pharmaceutical Form:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: >18 and 2 segments Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Other concomitant cardiac diseases Previous myocardial infarction Killip IV Women in childbearing age

Design outcomes

Primary

Measure	Time frame
Main Objective: Left ventricular eyection fraction Segmentary motility index Segmentary myocardial perfusion Segmentary myocardial viability Left ventricular volumes Scar size;Secondary Objective: Safety: rate of adverse events Analyze clinical and biological markers related to outcome ;Primary end point(s): Left ventricular eyection fraction Segmentary motility index Segmentary myocardial perfusion Segmentary myocardial viability Left ventricular volumes Scar size	—

Measure

Time frame

Main Objective: Left ventricular eyection fraction Segmentary motility index Segmentary myocardial perfusion Segmentary myocardial viability Left ventricular volumes Scar size;Secondary Objective: Safety: rate of adverse events Analyze clinical and biological markers related to outcome ;Primary end point(s): Left ventricular eyection fraction Segmentary motility index Segmentary myocardial perfusion Segmentary myocardial viability Left ventricular volumes Scar size

—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026